Clozapine is the only treatment with regulatory-recognition of lowering suicidal risk, at least in schizophrenia patients. It remains uncertain whether such effects extend to other drugs for psychosis.
Methods:
We searched for reports on rates of suicidal behavior during treatment with clozapine and other modern drugs for psychosis (aripiprazole, olanzapine, risperidone, quetiapine, and ziprasidone) versus comparison or control treatments and analyzed the contrasts by random-effect meta-analysis to obtain pooled odds ratios (ORs) with 95% confidence intervals (CIs).
Results:
We identified 35 paired comparisons of modern drugs for psychosis versus comparison or control treatments in 18 reports. There was moderate overall superiority of all agents tested over alternatives (OR = 0.522, p = 0.004). With clozapine, this effect was large (OR = 0.229, p < 0.0001) and consistent (7/7 trials), but significant antisuicidal effects were not found with other drugs for psychosis in 28 other trials (OR = 0.941, p = 0.497). Apparent efficacy of specific agents ranked: risperidone ⩾ olanzapine ⩾ aripiprazole ⩾ ziprasidone ⩾ mixed drugs for psychosis ⩾ quetiapine, but none of these differences was significant.
Conclusions:
An ability of clozapine to reduce risk of suicides and attempts in schizophrenia patients appears to be a unique effect not shared with other modern medicines indicated for schizophrenia or bipolar disorder.
CiprianiAHawtonKStocktonS, et al. (2013) Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ346: f3646–f3658.
5.
De FruytJDeschepperEAudenaertK, et al. (2012) Second generation antipsychotics in the treatment of bipolar depression: Systematic review and meta-analysis. J Psychopharmacol26: 474–486.
6.
FrazerABlierP (2016) A neuroscience-based nomenclature (NbN) for psychotropic agents. Int J Neuropsychopharmacol19: pyw066. DOI: 10.1093/ijnlp/pyw066.
7.
HaukkaJTiihonenJHärkänenT, et al. (2008) Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf17: 686–696.
8.
HayesJFPitmanAMarstonL, et al. (2016) Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood-stabilizer treatment: UK population-based electronic health records study. JAMA Psychiatry73: 630–637.
9.
HennenJBaldessariniRJ (2005) Reduced suicidal risk during treatment with clozapine: Meta-analysis. Schizophr Res73(2–3): 139–145.
10.
HuiCLMHonerWGLeeEHM, et al. (2018) Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: 10 year follow-up of a randomized, double-blind trial. Lancet Psychiatry5: 432–442.
11.
KarayalONAnwaySDBatzarE, et al. (2011) Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone. J Clin Psychiatry72: 367–375.
12.
KasckowJFelmetKZisookS (2011) Managing suicide risk in patients with schizophrenia. CNS Drugs25: 129–143.
13.
KhanAKoltsRLBrodheadAE, et al. (2006) Suicide risk analysis among patients assigned to psychotropics and placebo. Psychopharmacol Bull39: 6–14.
14.
KhanAFaucettJMorrisonS, et al. (2013) Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry70: 1091–1099.
15.
KhokharJYHenricksAMSullivanEDK, et al. (2018) Unique effects of clozapine: pharmacological perspective. Adv Pharmacol82: 137–162.
16.
KiviniemiMSuvisaariJKoivumaa-HonkanenH, et al. (2013) Antipsychotics and mortality in first-onset schizophrenia: Prospective Finnish register study with 5-year follow-up. Schizophr Res150: 274–280.
17.
KoekRJYerevanianBIMintzJ (2012) Subtypes of antipsychotics and suicidal behavior in bipolar disorder. J Affect Disord143(1–3): 27–33.
18.
LiberatiAAltmanDGTetzlaffJ, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med6: e1000100–e1000127.
19.
MathesTKlaßenPPieperD (2017) Frequency of data extraction errors and methods to increase data extraction quality: Methodological review. BMC Med Res Methodol17: 152–159.
20.
MedićBStojanovićMStimecBV, et al. (2020) Lithium—pharmacological and toxicological aspects: The current state of the art. Curr Med Chem27: 337–351.
21.
MeltzerHY (2005) Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. J Clin Psychiatry66: 530–533.
22.
MeltzerHYAlphsLGreenAI, et al. (2003) Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry60: 82–91.
23.
MeltzerHYBaldessariniRJ (2003) Reducing risk for suicide in schizophrenia and affective disorders. J Clin Psychiatry64: 1122–1129.
24.
ModestinJDal PianDAgarwallaP (2005) Clozapine diminishes suicidal behavior: Retrospective evaluation of clinical records. J Clin Psychiatry66: 534–538.
25.
MontastrucFNieRLooS, et al. (2019) Association of aripiprazole with risk for psychiatric hospitalization, self-harm, or suicide. JAMA Psychiatry76: 409–417.
26.
MulderRHamiltonAIrwinL, et al. (2018) Treating depression with adjunctive antipsychotics. Bipolar Disord20(Suppl. 2): 17–24.
NelsonJCPapakostasGI (2009) Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry166: 980–991.
29.
PompiliMBaldessariniRJForteA, et al. (2016) Do atypical antipsychotics have antisuicidal effects? A hypothesis-generating overview. Int J Mol Sci17: 1700–1712.
30.
ReutforsJBrennerPBrodyB, et al. (2020) Post-authorization safety study of quetiapine as antidepressant treatment in Sweden: Nested case-control analyses of select outcomes. Drug Safety43: 135–145.
31.
RheeTGOlfsonMNierenbergAA, et al. (2020) 20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry177: 706–715.
32.
Ringbäck-WeitoftGBerglundMLindströmEA, et al. (2014) Mortality, attempted suicide, re-hospitalization and prescription refill for clozapine and other antipsychotics in Sweden—A register-based study. Pharmacoepidemiol Drug Saf2014; 23: 290–298.
33.
RubertoVLJhaMKMurroughJW (2020) Pharmacological treatments for patients with treatment-resistant depression. Pharmaceuticals (Basel)13: 116–120.
34.
RuengornCSanichwankulKNiwatananunW, et al. (2011) Incidence and risk factors of suicide reattempts within 1 year after psychiatric hospital discharge. Clin Epidemiol3: 305–313.
35.
ThomasJLHJiangYMcCombsJ (2015) Clozapine revisited: Impact of clozapine vs. olanzapine on healthcare use by schizophrenia patients on Medicaid. Ann Clin Psychiatry27: E1–E10.
36.
TiihonenJLönnqvistJWahlbeckK, et al. (2009) Eleven-year follow-up of mortality in patients with schizophrenia: Population based cohort study. Lancet364(9690): 620–627.
37.
TondoLBaldessariniRJ (2016) Suicidal behavior in mood disorders: Response to pharmacological treatment. Curr Psychiatry Rep18: 88–98.
38.
TournierMNeumannAPambrunE, et al. (2019) Conventional mood-stabilizers or second-generation antipsychotic drugs in bipolar disorders: Population-based comparison of risk of treatment failure. J Affect Disord257: 412–420.
39.
WalkerAMLanzaLLArellanoF, et al. (1997) Mortality in current and former users of clozapine. Epidemiology8: 671–677.
40.
WeislerRMontgomerySAEarleyWR, et al. (2014) Extended release quetiapine fumarate in patients with major depressive disorder: Suicidality data from acute and maintenance studies. J Clin Psychiatry75: 520–527.
